Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 24, showing 10 Applications out of 238 total, starting on record 31, ending on 40

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

31.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
18-09-2020 View

32.

ECCT/25/07/08   REACH
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre,   non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Nakuru Level 5 Hospital (Nakuru county)
 
17-12-2025 View

33.

ECCT/20/10/02   MALCOV
    Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso (MALCOV)   
Principal Investigator(s)
1. Simon Kariuki
2. Helen Barsosio
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOORTH), (Kisumu county)
2. Kisumu County Referral Hospital. (Kisumu county)
3. Alupe sub-County Hospital, (Busia county)
4. Bondo sub-County Hospital, (Siaya county)
5. Macalder (Nyatike) sub-County Hospital (Migori county)
6. Migori County Teaching and Referral Hospital; (Migori county)
 
23-11-2020 View

34.

ECCT/15/01/05   In vivo efficacies of AL and DP
    Open label randomized study evaluating the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children under five years of age in western Kenya.   
Principal Investigator(s)
1. AAron Samuels
2. Simon Kariuki
Site(s) in Kenya
Siaya District Hospital
 
03-03-2015 View

35.

ECCT/23/04/04   AGREE
    Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
1. Ahero County Hospital (Kisumu county)
2. Alupe sub-county Hospital (Busia county)
3. Siaya County Referral Hospital (Siaya county)
 
24-08-2023 View

36.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
14-05-2024 View

37.

ECCT/24/04/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Fredrick Kipyego Sawe
Site(s) in Kenya
1. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
 
03-07-2024 View

38.

ECCT/24/05/05   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Kariuki Simon Kariuki
2. Patricia Odero Ojwang
Site(s) in Kenya
1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county)
 
29-08-2024 View

39.

ECCT/24/09/01   L9LS-PD
    Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd)   
Principal Investigator(s)
1. Mary Iwaret Otiti
Site(s) in Kenya
1. Homa Bay County Teaching and Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
 
16-03-2025 View

40.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
04-08-2024 View